InBios Receives FDA 510(k) Clearance for COVID-19 POC Antigen Detection Test

InBios Launches an In Vitro Diagnostic Test for Strongyloidiasis Providing Fast Results

InBios Awarded New Contract to Supply COVID-19 Tests

FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios

InBios Awarded Funding for Lyme Disease Diagnostic from HHS, Cohen Foundation

Rapid Antigen Tests Accurately Detect COVID Variants

Antigen Tests Accurately Detect COVID-19 Variants in Study

InBios Featured on NBC COVID-19 Update

Manufacturers Rush to Ramp Up Rapid COVID Test Production

Companies Produce ‘Tens of Millions’ More Rapid COVID Tests

U.S. Testing Struggles to Keep Up with Omicron

InBios Receives FDA EUA for Home Use Antigen Test for COVID-19

InBios Receives FDA EUA for COVID-19 Neutralizing Antibody ELISA

InBios Receives FDA EUA for COVID-19 IgG Antibody Rapid Test

New Studies Suggest InBios COVID-19 POC Antigen Test Will Detect Delta Variant

Curebase, InBios Announce Results of Virtual Clinical Trial

InBios Receives FDA EUA for COVID-19 POC Antigen Detection Test

InBios Awarded Contract Through US Army for SCoV-2 Infection Clinical Trials

InBios Awarded $12.7M to Boost Production of Two COVID-19 Diagnostics

DoD Awards $12.67 Million Contract Action to InBios International Inc.

InBios Gets FDA EUA for Second Coronavirus Antibody Test

InBios Receives FDA EUA for Second COVID-19 Antibody Test

InBios Receives FDA EUA for COVID-19 Antibody Test

InBios Nabs FDA EUA for SARS-CoV-2 Assay

InBios Obtains BARDA Funding to Develop Point of Care COVID-19 Test

InBios Awarded Contract from BARDA for COVID-19 Rapid Test

InBios receives FDA Emergency Use Authorization for its Smart Detect SARS-CoV-2 rRT-PCR Kit for Detection of the Virus causing COVID-19

InBios Gets FDA Emergency Use Authorization for SARS-CoV-2 Kit

Amid Coronavirus Outbreak, FDA and Industry Seek Roadmap

Evaluation of Chagas RDTs Shows High Accuracy in Endemic Region

FDA Approves Diagnostic Test for Zika Virus

Seattle’s InBios: First to Receive FDA Authorization for Zika Test

First Diagnostic Test for Zika Gets FDA’s OK to Market

InBios Receives FDA Market Authorization for its ZIKV Detect 2.0 IgM Capture ELISA for a Presumptive Diagnosis of Zika Virus Infection

FDA Grants Marketing Authorization for First Diagnostic Test for Detecting Zika IgM Antibodies to InBios

InBios announces FDA clearance of its Dengue NS1 ELISA kit

InBios announces FDA emergency use authorization for its Zika ELISA

As Zika Virus Spreads, Gaps In Diagnostic Testing Present Opportunities For Drug Companies

UTMB researchers help discover simple, affordable diagnostic kit for chikungunya

Leishmania Rapid Diagnostic Device Receives FDA Clearance

FDA Clearance: CL Detect™ Rapid Test
Read US Army Medical Research and Material Command Press Release…

USDA Licenses InBios’ West Nile ELISA for Equine
Read the press release

New Dengue IgM ELISA Study
Read the article

InBios Keeps Pace With West Nile Outbreak
Read the article…

FDA Clearance: Dengue IgM ELISA
Read the FDA press release…

ISO Certified
InBios is ISO 13485:2003 certified.

FDA Clearance: InBios’ West Nile IgM ELISA
InBios has received 510(k) clearance from the Food and Drug Administration for its West Nile Detect IgM Capture ELISA. This in vitro diagnostic assay is highly sensitive and specific for the West Nile Virus. This kit is available worldwide.

FDA Clearance: Kalazar Detect Rapid Test
InBios has received 510(k) clearance from the Food and Drug Administration for its Kalazar Detect Rapid Test. This kit is available worldwide.